Providence researchers contribute to 21 studies at SITC2023

The annual Society for Immunotherapy of Cancer (SITC) meeting held Nov. 1-5, in San Diego, CA., was an exciting time for experts in the field to gather and discuss their work in cancer immunotherapy. Researchers, physicians, clinicians and students from around the world presented their research via oral and poster abstract presentations, mingled and enjoyed camaraderie in the warm Southern California sun. 

Researchers and oncologists from Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, attended the conference, contributing to 21 abstracts selected for poster presentations and an oral presentation.   

Additionally, Bernard Fox, Ph.D., gave opening and closing statements at the World Immunotherapy Council Young Investigator Symposium on opening day. Rachel Sanborn, M.D. served as a session co-chair in the Concurrent Session 107d: Oral Abstract Session; and Brian Piening Ph.D., and Rom Leidner, M.D., spoke at the sponsored symposia, presenting the study, “Using hyperplex immunofluorescence to characterize the immune response to iSABR in head and neck cancer.” 

Rom Leidner, M.D.

The following is a full list of abstracts by Providence researchers and oncologists.   

Oral Presentation 

Regular and Young Investigator Award Abstracts | Combination Immunotherapies 

Abstract 878: T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants 
Andrew Weinberg, Ph.D., et al. 

Poster Presentations 

Category: Biomarkers, Immune Monitoring and Novel Technologies 

Abstract 30: Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial 
Brendan Curti, M.D., et al. 

Abstract 65: Development and optimization of a broad hyperplex immunofluorescence assay for tumor immune microenvironment characterization 
Carlo Bifulco, M.D., Brian Piening, Ph.D., et al.  

Abstract 142: Detection of KRAS G12D/G12V neoepitopes expressed by cancer cell lines using LC-MS/MS 
William Redmond, Ph.D., Brian Piening, Ph.D., Bernard Fox, Ph.D., Eric Tran, Ph.D., et al. 

Abstract 148: Characterizing Cancer’s Dark Matter, Short-lived Proteins, and Defective Ribosomal Products, Presented by Cancer and Contained in the DPV-001 Cancer Vaccine 
William Redmond, Ph.D., Carlo Bifulco, M.D., Rachel Sanborn, M.D., R. Bryan Bell, M.D., D.D.S., FACS, Walter Urba, M.D., Ph.D., Rom Leidner, M.D., Brian Piening, Ph.D., Bernard Fox, Ph.D., et al. 

Abstract 149: Simultaneous identification of KRAS mutation-carrying multiple neoepitopes by differential ion mobility-assisted targeted-mass spectrometry 
Eric Tran, Ph.D., William Redmond, Ph.D., Brian Piening, Ph.D., Bernard Fox, Ph.D., et al. 

Category: Immune monitoring, Solid tumors, T cell, B cell, Vaccine 

Abstract 680: Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma 
Matthew Taylor, M.D., William Redmond, Ph.D., Brady Bernard, Ph.D., R. Bryan Bell, M.D., D.D.S., FACS, Carlo Bifulco, M.D., et al. 

Abstract 954: Fluorescence tracking demonstrates a rapid cycle of Treg recirculation to tumor draining lymph nodes and back to tumors that is interrupted by radiation therapy 
Marka Crittenden, M.D., Ph.D., Michael Gough, Ph.D., et al. 

Abstract 1013: NKG2A expression on tumor reactive CD8 T cells is induced by IL-12    
Jianguo Huang, Ph.D., Thomas Duhen, Ph.D., et al. 

Category: Antibody, Clinical study, Clinical trial, Tumor antigens, Targeted therapy 

Abstract 718: Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies 
Brendan Curti, M.D., et al. 

Category: Checkpoint blockade, Clinical trial, Cytokine, Solid tumors, T cell, Tumor microenvironment, Tumor infiltrating lymphocytes  

Abstract 737: A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumor 
Brendan Curti, M.D., et al.  

Category: Clinical trial, Dendritic cell, TLR, Antigen presenting cells, Solid tumors 

Abstract 763:Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies 
Brendan Curti, et al. 

Category: Biomarkers, Bioinformatics, Immune contexture, Immune monitoring, T cell, Tumor infiltrating lymphocytes, Tumor microenvironment 

Abstract 124: Location, location, location: Spatial analysis of ultrahigh-plex immunofluorescence panel in head and neck cancer 
Rom Leidner, M.D., Bernard Fox, Ph.D., et al. 

Category: Tumor and Stromal Cell Biology 

Abstract 1487: PD-1 expression on tumor-infiltrating T-lymphocytes as determinant of the head and neck cancer tumor immune microenvironment rather than anatomical site 
Bernard Fox, Ph.D., et al. 

Category: Novel Single-Agent Immunotherapies 

Abstract 1360: Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice 
William Redmond, Ph.D., et al. 

Category: Clinical Trial in Progress 

Abstract 735: Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer 
Rachel Sanborn, M.D., et al.  

Abstract 679: Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16 positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a Phase 1 study 
Rom Leidner, M.D., et al. 

Abstract 742: Phase 1/2 study of the bispecific 4-1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors 
Rachel Sanborn, M.D., et al.  

Abstract 748: Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors 
Rachel Sanborn, M.D., et al. 

Category: Combination Immunotherapies 

Abstract 834: Retinoid X receptor agonists enhances type I systemic and intratumoral immunity, but enhanced tumor prevention, with the HER2-IGFBP2-IGF1R plasmid vaccine in two mouse mammary tumor models 
Sasha Stanton, M.D., Ph.D., et al. 

Category: Clinical Trial Completed 

Abstract 594: SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+ tumors treated with cell-based vaccine, SQZ-PBMC-HPV 
Matthew Taylor, M.D., et al. 

Learn more about the annual SITC meeting.  

Providence center of excellence for precision immuno-oncology and cellular therapy 

Since 1993, cancer research has been the primary focus of the Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute of Oregon. Under the leadership of Walter J. Urba, M.D., Ph.D., our team of physicians and scientists work together to improve cancer treatment methods – seamlessly joining lab research and clinical trials with patient care. 

Our main area of research is cancer immunotherapy, and with the advancements in genomic sequencing we bring together the power of immunotherapy and personalized medicine to accelerate leading-edge research and groundbreaking discoveries for patients with cancer. 

To learn more about Earle A. Chiles Research Institute: 

Related news

New studies address unmet needs in treating triple-negative breast cancer

Dr. Urba receives award for his contributions to science and community

Providence researchers contribute to more than 20 studies presented at ASCO Annual Meeting

2/26/2024
Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.
2/9/2024
In honor of International Day of Women and Girls in Science we highlight a researcher at Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute.
2/1/2024
Providence Cancer Institute registered dietitian to present a free virtual education talk on nutrition in March.
1/24/2024
New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy